TABLE 2.
Salvage therapy according to age
| Salvage therapy | Age ≤65 years | Age >65 years |
|---|---|---|
| (n = 34) | (n = 29) | |
| Systemic chemotherapy, n a | 24 | 18 |
| ESHAP b | 9 | 1 |
| CODOX‐M/IVAC c | 6 | 0 |
| IVAC | 2 | 0 |
| DHAP d | 2 | 0 |
| EPOCH e | 1 | 3 |
| ICE f | 1 | 1 |
| CMOPP g | 0 | 8 |
| Other | 3 | 5 (4 trials) |
| Local treatment, n | 10 | 11 |
| Radiation therapy for CNS disease h | 4 | 6 |
| Radiation therapy for extra‐CNS disease | 5 | 5 |
| Total gastrectomy | 1 | 0 |
a
Systemic chemotherapy performed with or without monoclonal anti‐CD20 antibody.
b
ESHAP, etoposide, methylprednisolone, high‐dose cytarabine, and cisplatin.
c
CODOX‐M, cyclophosphamide, doxorubicin, vincristine, and high‐dose methotrexate; IVAC, ifosfamide, etoposide, and high‐dose cytarabine.
d
DHAP, dexamethasone, high‐dose cytarabine, and cisplatin.
e
EPOCH, etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin.
f
ICE, ifosfamide, carboplatin, and etoposide.
g
CMOPP, cyclophosphamide, vincristine, prednisolone, and procarbazine.
h
CNS, central nervous system.